NCT06532799 - TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 10, 2024

Primary Completion Date

December 15, 2025

Study Completion Date

December 28, 2026

Conditions

Stomach CancerStomach Cancer RecurrentStomach Cancer, AdenocarcinomaEsophageal CancerEsophageal Cancer Metastatic to BoneEsophageal Cancer Metastatic to LungEsophageal Cancer Metastatic to Liver

Interventions

BIOLOGICAL

Tumor Infiltrating Lymphocytes (TIL)

Tumor Infiltrating Lymphocytes (TIL) IV

DRUG

Cyclophosphamid

Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.

DRUG

Fludarabine

Fludarabine will be administered as an intravenous (IV) infusion for five days.

DRUG

Interleukin-2

After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.

DRUG

Pembrolizumab

Intravenous (IV) infusion

Trial Locations (1)

086-373

RECRUITING

District One Hospital, Beijing